Welcome to our dedicated page for Boston Scientific news (Ticker: BSX), a resource for investors and traders seeking the latest updates and insights on Boston Scientific stock.
Boston Scientific Corp. (BSX) is a leading global medical technology company that specializes in the development, manufacture, and marketing of medical devices for interventional medical procedures. The company's operations are divided into two main segments: MedSurg and Cardiovascular. With a focus on less invasive medical devices, Boston Scientific's products are designed for insertion into the human body through small openings or cuts, making them essential in various medical fields.
The company's product portfolio includes devices for angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and the treatment of incontinence. Boston Scientific markets its innovative solutions to healthcare professionals and institutions worldwide, with nearly half of its total sales coming from foreign markets.
Recently, the company made headlines with a successful public offering of €2,000,000,000 in aggregate principal amount of notes. These funds are intended to finance the acquisition of Axonics, Inc. and to repay existing debt, showcasing Boston Scientific's strategic financial management.
Significant advancements include the FDA approval for the AGENT™ Drug-Coated Balloon (DCB), aimed at treating coronary in-stent restenosis in patients with coronary artery disease. This novel device marks the first drug-coated coronary balloon available in the U.S., providing a dedicated treatment option for this challenging condition.
Boston Scientific is also expanding its strategic cooperation with Scivita Medical Technology Co., Ltd., focusing on the development and global distribution of endoscopic devices. This collaboration underscores the company's commitment to advancing medical technologies that enhance patient care.
On the financial front, Boston Scientific reported net sales of $3.856 billion for the first quarter of 2024, a 13.8% increase from the previous year. The company's diverse portfolio and robust pipeline, including the recent launch of the FARAPULSE™ Pulsed Field Ablation System, have been key drivers of this growth.
Looking ahead, Boston Scientific is actively involved in clinical trials such as the NAVIGATE-PF study for the FARAWAVE™ Nav Pulsed Field Ablation Catheter and the MODULAR ATP trial for the mCRM™ System. These trials aim to further improve patient outcomes and expand the company's product offerings.
As a global leader in medical technology, Boston Scientific remains committed to transforming lives through innovative solutions that address unmet patient needs and reduce healthcare costs. Stay updated with the latest developments by visiting their website and connecting on LinkedIn and X, formerly Twitter.
Boston Scientific Corporation (NYSE: BSX) announced the acquisition of Obsidio, Inc. on August 15, 2022. The acquisition incorporates Obsidio's Gel Embolic Material (GEM™) technology, recently cleared by the FDA, into Boston Scientific's interventional oncology and embolization portfolio. GEM technology is designed for efficient embolization procedures, offering advantages over current embolics by providing immediate obstruction of blood flow. The transaction is expected to have an immaterial impact on Boston Scientific's earnings in 2022.
Nevro Corp. and Boston Scientific Corp. have resolved their intellectual property litigation through a settlement. This agreement allows Boston Scientific to operate with its current products utilizing features below 1,500 Hz while granting Nevro similar freedoms. Nevro will license paresthesia-free therapy technology to Boston Scientific, and vice versa. The settlement also includes a net payment of $85 million from Boston Scientific to Nevro, concluding all ongoing litigations between the two parties.
Boston Scientific generated $3.244 billion in net sales for Q2 2022, marking a 5.4% year-over-year increase. GAAP net income reached $246 million or $0.17 per share, compared to $172 million or $0.12 per share in 2021. Adjusted EPS improved to $0.44 from $0.40. Segments such as MedSurg and Cardiovascular reported solid growth, with emerging markets soaring 18.9%. However, U.S. growth was strong at 7.4%, while EMEA faced a slight decline of (0.3%). The company expects 6.5% to 7.5% growth for the full year and continued operational success.
Boston Scientific will host a conference call on July 27, 2022, at 8:00 a.m. EDT to discuss its second-quarter financial results for the period ending June 30, 2022. The call will feature CEO Mike Mahoney and CFO Dan Brennan. A news release detailing the financial results will be issued prior to the call. Investors can access the live webcast and subsequent replay on the company’s investor relations website.
Boston Scientific Corporation (NYSE: BSX) has entered into a definitive agreement to acquire a 64% stake in M.I.Tech Co., Ltd., a Korean medical device manufacturer, for approximately $230 million. M.I.Tech is known for its HANAROSTENT™ technology, which features self-expanding metal stents used in various minimally invasive medical procedures. This acquisition is expected to enhance Boston Scientific's stent portfolio and expand M.I.Tech's international presence. The transaction is scheduled to close in the second half of 2022, with an immaterial impact on earnings projected for that year.
Boston Scientific Corporation (NYSE: BSX) will participate in the Bank of America Global Healthcare Conference on May 12, 2022. The session will feature Dan Brennan, CFO, and Lauren Tengler, VP of Investor Relations, and is scheduled for 8:00 a.m. PT. A live webcast will be available on the company's Investor Relations website. Replay access will be provided approximately an hour after the event concludes. Boston Scientific focuses on innovative medical solutions that enhance patient health worldwide.
Boston Scientific Corporation (BSX) reported Q1 2022 net sales of $3.026 billion, reflecting a 10.0% increase year-over-year. GAAP net income was $97 million or $0.07 per share, down from $327 million or $0.23 per share a year ago. Adjusted EPS was $0.39, slightly up from $0.37. Growth was driven by all reportable segments, with notable increases in Cardiovascular (11.4%) and MedSurg (9.1%). However, GAAP EPS fell below the anticipated $0.16 to $0.20. The company remains optimistic for full-year growth despite macroeconomic challenges.
Boston Scientific Corporation (NYSE:BSX) will host a conference call on April 27, 2022, at 8:00 a.m. EDT, to discuss financial results for the first quarter ended March 31, 2022. The call will feature Mike Mahoney, CEO, and Dan Brennan, CFO, with a corresponding news release issued prior to the call. Interested parties can access the live webcast and replay at investors.bostonscientific.com.
Boston Scientific Corporation (NYSE:BSX) announced the pricing terms for its upsized cash tender offer totaling $2.85 billion for outstanding senior notes. The offer will expire on March 29, 2022 unless extended. Holders tendering before the Early Tender Date (March 15, 2022) may receive a $30 per $1,000 principal Early Tender Payment. These transactions are expected to be accretive to adjusted earnings per share by $0.02 in 2022, despite a projected $200 million charge on a GAAP basis.
Boston Scientific (BSX) announced results of its cash tender offer for up to $2.5 billion in senior notes, which received valid tenders of $5.139 billion by the early tender date of March 15, 2022. Due to high demand, the company has increased the maximum principal amount to $2.85 billion. The tender offer will expire on March 29, 2022. Holders of accepted securities will receive a $30 early tender payment and accrued interest.
FAQ
What is the current stock price of Boston Scientific (BSX)?
What is the market cap of Boston Scientific (BSX)?
What does Boston Scientific Corp. specialize in?
What are the main segments of Boston Scientific?
What recent financial achievement has Boston Scientific announced?
What is the AGENT™ Drug-Coated Balloon (DCB)?
What is the focus of Boston Scientific’s latest clinical trials?
How has Boston Scientific performed financially in 2024?
What are some key products manufactured by Boston Scientific?
How much of Boston Scientific’s sales come from international markets?
Who are Boston Scientific’s customers?
What is Boston Scientific's vision for the future?
